Official EMA announcements

Eli Lilly's Kisunla™ Receives FDA Approval for Early Symptomatic Alzheimer's Treatment

Jul 2, 2024, 05:39 PM

Eli Lilly's Kisunla™ (donanemab-azbt) has received FDA approval for the treatment of early symptomatic Alzheimer's disease. The new amyloid-targeting therapy is designed to slow cognitive decline by up to 35% and reduce the risk of disease progression. Kisunla™ is the second drug cleared in the US to slow the progression of Alzheimer's, a condition affecting 6 million Americans. The treatment involves 13 30-minute infusions over 12 months, costing $32,000. Eli Lilly intends to donate Kisunla™ to the Lilly Cares Foundation.